Measure the reduction in the field of rare diseases
Formed by companies who research, The Spanish Association of Laboratory Orphan and Ultra-Orphan (AELMHU) develop and market drugs to treat rare diseases and ultra-rare, has expressed grave concern at the extent of reduction of 15 per cent of the prices of innovative medicines, which are more than 10 years in the market and do not have generic, approved by the Inter-Territorial Council of the National Health (CISNS).
AELMHU believes that “if the government decides to implement this measure of reduction in the area of ??rare diseases, will seriously jeopardize the future ability of firms to continue investing in research to develop new drugs that address the needs health of these patients. “
From this partnership will also include noting that “saving for the health system will be minimal because, due to the low prevalence of rare diseases, spending on ultra-orphan drugs and orphan in the health budget is negligible.”
Also remember that “many of the companies that market orphan drugs are newly formed, very small in terms of infrastructure and even some of them have one marketed product. These companies invest and continue to invest in R + D + i Spain. ” Therefore, according AELMHU, “a discount applied in this area would be a serious threat to the viability of these companies, engine research and development of new drugs for diseases without therapeutic alternatives.”
“The NHS should ensure continued support in the area of ??rare diseases in order to produce efficient investment that makes available to patients in a growing stream of innovative orphan drugs,” they say from the association. So, believe “strongly” that the ultra-orphan drugs and orphan should be excluded from this reduction in prices of innovative medicines that carry more than 10 years on the market.